Subtype
Colon Adenocarcinoma
CI-CAN-00007498Explore in graph →
28 active trials1 approved drugs7 evidence items
- NCIt
- C4349
- OncoTree
- COAD
- DOID
- 234
- UMLS CUI
- C0338106
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007498Explore in graph →
Clinical trials
132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (22)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05868226 | PRE-ISPY Phase I/II Oncology Platform Program(PRE-ISPY) | recruiting | Phase 1 / Phase 2 | 280 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07595874 | Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3(NEST3) | recruiting | Phase 2 | 100 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 |
| clinicaltrials |
| NCT07468630 | Tolecizumab Plus Chemoimmunotherapy for pMMR/MSS Locally Advanced Colon Adenocarcinoma(TRIUNITE-08) | recruiting | Phase 2 | 106 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT07462650 | Dual-Target CAR-NK Cells for Biomarker-Selected Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 48 | Beijing BiotechINDUSTRY | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06640166 | Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.(ECLYPse) | recruiting | Phase 2 | 25 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06709885 | HDAC Inhibitor Combination With Chemoimmunotherapy in the Neoadjuvant Treatment of pMMR Locally Advanced Colon Cancer | recruiting | Phase 2 | 100 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Nov 29, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Sep 2, 2026source: clinicaltrials